Carbon Black Tattoo in Colon Cancer

NCT ID: NCT03705754

Last Updated: 2022-05-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-06

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to elucidate whether carbon black suspension endoscopic tattoo enhances visibility of lymph nodes or tumor tissue on dissection of colonic surgical specimen, thereby making improvement in staging defined as better pTNM stage via better visualisation of carbon marked metastatic or sentinel lymph nodes or marked primary tumor or adjacent tissues.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Other objectives are:

* to assess intraoperative visibility of carbon black tattoo in the tumor region and surrounding tissues
* to assess microscopic distribution of carbon ink in the layers of the colonic wall and adjacent tissues
* to assess complications related to carbon black tattoo procedure like microscopic fibrosis, micro- or macroscopic scarring, inflammatory reactions
* to assess long-term effects of ink injections on control endoscopies at 6 and 12 months
* to assess dissection time in tattooed-non tattooed lymphatic tissues

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endoscopic Tattoo of Suspected Colon Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Tattoo arm vs. control arm
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tattoo arm

Tattoo will be placed by endoscopic submucosal injection of carbon black suspension

Group Type ACTIVE_COMPARATOR

carbon black suspension colonic tattoo injection

Intervention Type DEVICE

Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.

Control arm

Tattoo will not be placed but case will follow standard procedure

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

carbon black suspension colonic tattoo injection

Examine the SPOT syringe to verify that the pigment is fully suspended. A 23 or 25 G sclerotherapy needle is recommended for this procedure, attach the syringe and prime with SPOT. After injection catheter is primed, manoeuver with the endoscope for optimal injection position and inject tangentially, at a 30-40˚ angle to the mucosa and create a saline bleb to find the submucosal plane prior to injecting SPOT to reduce risk of intramural injection. Document both the depth of scope and anatomic location of each tattoo and the ink consumption as well. Place injection 2-3 cm distal (downstream) of the area of interest. Use 0.5-0.75 mL per injection site and no more than 8 mL per patient. Place SPOT tattoos in 3-4 quadrants around the lumen to increase likelihood of visualisation.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GI supply SPOT endoscopic marker

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female aged 18 years or above undergoing colonoscopy for suspected colonic malignancy
* Participant is able to give informed consent for participation in the study
* Patient is presumably selected for surgery within 30 days following tattoo injection

Exclusion Criteria

* Patients under the age of 18
* Patients unable to give informed consent or ineligible for surgery
* Tumor in the coecum dome or in the rectum (\<15 cm)
* Known allergy to suspension ingredients
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Szeged University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Matyas Czepan

Head of Division of Internal Medicine 2/S

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Matyas Czepan, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Szeged University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

1st Department of Medicine, University of Szeged

Szeged, Csongrád megye, Hungary

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Hungary

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Matyas Czepan, MD, PhD

Role: CONTACT

+3662545189

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mátyás Czepán

Role: primary

+3662545189

References

Explore related publications, articles, or registry entries linked to this study.

Askin MP, Waye JD, Fiedler L, Harpaz N. Tattoo of colonic neoplasms in 113 patients with a new sterile carbon compound. Gastrointest Endosc. 2002 Sep;56(3):339-42. doi: 10.1016/s0016-5107(02)70035-7.

Reference Type RESULT
PMID: 12196769 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019/CCT

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SGM-101 in Colorectal Lung Metastases
NCT04737213 UNKNOWN PHASE2